Newsletters

[Cancer Immunology Research] Scientists reported that the prostate-specific membrane antigen (PSMA) Tri-specific Killer Engager specifically bound to PSMA-expressing cells and significantly enhanced expansion, degranulation, and cytokine production of NK cells derived from healthy donors or prostate cancer patients.

[Advanced Science] Researchers demonstrated that under enzalutamide treatment, osteoblasts in the bone microenvironment secrete increased levels of extracellular matrix protein 1 (ECM1), which affected surrounding prostate cancer cells, promoting tumor cell proliferation and anti-androgen resistance.

[Nature Communications] Scientists discovered that striatal astrocytes occupied a cell type-specific anatomical and functional relationship with cholinergic interneurons (ChIs), through which they rapidly excited ChIs and governed dopamine release via nicotinic acetylcholine receptors on subsecond timescales.

[Advanced Science] Scientists generated iPSCs and cerebral organoids from three individuals with idiopathic nonregressive autism spectrum disorder presenting with normocephaly. Multiple cell lines and time series single-cell sequencing evealed premature differentiation of neural stem cells in organoids as well as defective expression of fatty acid binding protein 7 (FABP7).

[Cell Death & Disease] Researchers showed that gains of 1q impacted the differentiation capacity to derivates of the three germ layers, leading to mis-specification to cranial placode and non-neural ectoderm during neuroectoderm differentiation.

[Nature Communications] Scientists established metrics for grading the resemblance of blastoids to mouse blastocysts, and identified the differential activation of gene regulons involved in lineage specification among various blastoid grades.

[Nature Communications] Scientists introduced the Spatial and Cell-type Proteomics platform, termed SCPro, which was employed to explore the pancreatic tumor microenvironment. It revealed the spatial alternations of over 5000 proteins by automatically dissecting up to 100 single cells.

[Signal Transduction and Targeted Therapy] This Phase Ib trial study assessed the efficacy and safety of the combination of neoadjuvant oncolytic virus orienX010 (ori) and anti-PD-1 toripalimab (tori) for resectable acral melanoma (AM). Neoadjuvant ori and tori demonstrated antitumor activity with high response rates for AM with acceptable tolerability.

[Nature Communications] Researchers unveiled the casein kinase 1δ as an uncharacterized regulator of oncogenic NRAS mutations, specifically Q61R and Q61K, which are the most prevalent NRAS mutations in melanoma.

[Nature Communications] Scientists introduced a stepwise paradigm in which Smad2/3 regulated the lineage priming and differentiation of mouse ESCs by collaboration with different effectors.

[Nature] Scientists identified a small compound, gliocidin, that killed glioblastoma cells while sparing non-tumour replicative cells. Gliocidin activity targeted a de novo purine synthesis vulnerability in glioblastoma through indirect inhibition of inosine monophosphate dehydrogenase 2.

[Cell Death Discovery] The authors present a comprehensive review of Alzheimer’s disease-associated deubiquitinating enzymes (DUBs) and elucidate their physiological roles. They review current advancements in developing inhibitors targeting these DUBs, including the determination of cocrystal structures with their respective targets.